Novavax (NVAX) EVP granted 139,500 non-statutory stock options

Rhea-AI Filing Summary

NOVAVAX INC executive vice president of research and development Ruxandra Draghia-Akli reported an amended insider filing related to a previously disclosed stock option grant. On March 2, 2026, she was granted a non-statutory stock option covering 139,500 shares, held directly.

According to the filing, this Form 4/A was filed solely to amend the exercise price previously reported; all other information from the original March 5, 2026 Form 4 remains unchanged. One quarter of the option vests on the first anniversary of March 2, 2026, with the remaining three quarters vesting in equal monthly installments over the following three years, subject to continued employment.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Draghia-Akli Ruxandra

(Last) (First) (Middle)

21 FIRSTFIELD ROAD

(Street)

GAITHERSBURG MD 20878

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
NOVAVAX INC [ NVAX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, Research & Development

3. Date of Earliest Transaction (Month/Day/Year)
03/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)
03/05/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Non-Statutory Stock Option NQ	$10.11(1)	03/02/2026		A		139,500		(2)	03/02/2036	Common Stock	139,500	$0(1)	139,500	D

Explanation of Responses:

1. This Form 4/A has been filed solely to amend the exercise price as originally reported in Column 2 and price of derivative security as originally reported in Column 8 of Table II of the Reporting Person's Form 4 filed on March 5, 2026. All other information remains unchanged from the March 5, 2026 filing.

2. One quarter (1/4) of the shares subject to this option granted under the Plan vest on the first anniversary of March 2, 2026, and the remaining three-quarters (3/4) of the shares vest in equal monthly installments over the following three (3) years, in each case subject to continued employment with the Company through such vesting date.

	/s/ Mark J. Casey, Attorney-in-Fact	03/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Novavax (NVAX) report for Ruxandra Draghia-Akli?

Novavax reported that EVP of R&D Ruxandra Draghia-Akli received a grant of non-statutory stock options for 139,500 shares on March 2, 2026. The options are held directly and were disclosed in an amended Form 4/A filing.

Why did Novavax file a Form 4/A amendment for NVAX?

Novavax filed Form 4/A solely to amend the exercise price reported for a previously disclosed option grant. The amendment corrects the figures in specific columns, while all other details from the original March 5, 2026 Form 4 remain unchanged.

How many stock options were granted to the Novavax EVP of R&D?

The EVP of Research & Development at Novavax, Ruxandra Draghia-Akli, was granted 139,500 non-statutory stock options. This entire amount is shown as acquired in a single transaction dated March 2, 2026 and is reported as directly owned.

What is the vesting schedule for Ruxandra Draghia-Akli’s Novavax stock options?

The non-statutory stock options vest over four years: one quarter of the shares vest on the first anniversary of March 2, 2026, and the remaining three quarters vest in equal monthly installments over the following three years, subject to continued employment.

Does the Novavax Form 4/A change any information besides the exercise price?

No. The Form 4/A explicitly states it was filed solely to amend the exercise price fields for the option grant. All other information, including the number of options and vesting terms, remains unchanged from the March 5, 2026 Form 4.

What role does Ruxandra Draghia-Akli hold at Novavax in this Form 4/A?

In this filing, Ruxandra Draghia-Akli is identified as Novavax’s Executive Vice President, Research & Development. The Form 4/A reports her receipt of a non-statutory stock option award and clarifies the corrected exercise price details for that grant.